Zia Rehman, MD
Pulmonary Disease · Greenville, NCNPI 1457396632
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.7%), travel and lodging and education — rather than concentrated in one kind of arrangement. ZOLL Respicardia, Inc. accounts for 67.6% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $3,037 and has fallen 95.6% since, to $135 in 2025.
Across 25 payments — averaging $167.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Respicardia, Inc.$3K
- AstraZeneca$410
- GSK$348
- Inari Medical, Inc.$142
- Inspire Medical Systems, Inc.$100
- Actelion Pharmaceuticals US, Inc.$92
- plus $265 from 5 others
Across 1 payment — averaging $95,147 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$95K
What the payments were for
- Travel & lodging$1,71341%
- Food & beverage$2,45559%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Respicardia, Inc. | 3 | $2,827 |
| AstraZeneca | 5 | $410 |
| GSK | 4 | $348 |
| Inari Medical, Inc. | 1 | $142 |
| Inspire Medical Systems, Inc. | 1 | $100 |
| Actelion Pharmaceuticals US, Inc. | 1 | $92 |
| Merck | 1 | $89 |
| Pulmonx Corporation | 1 | $88 |
| Chiesi USA, Inc. | 1 | $52 |
| Boston Scientific | 1 | $21 |
| United Therapeutics Corporation | 6 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- remede System$2,827
- TEZSPIRE$375
- CT THROMBECTOMY SYSTEM KIT$142
- FLOWTRIEVER CATHETER, S$142
- NUCALA$125
- TRELEGY ELLIPTA$124
- Inspire$100
How this compares
$4,183 in reported general payments places this provider in the 65th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 73 | $906,325 |
| AdempasRiociguat | 25 | $340,849 |
| UptraviSelexipag | 13 | $328,874 |
| XolairOmalizumab | 33 | $122,682 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 147 | $103,316 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 131 | $66,201 |
| Breo ElliptaFluticasone/Vilanterol | 107 | $54,342 |
| NucalaMepolizumab | 12 | $47,884 |
| Spiriva RespimatTiotropium Bromide | 71 | $43,661 |
| Incruse ElliptaUmeclidinium Bromide | 76 | $28,184 |
| Spiriva HandihalerTiotropium Bromide | 24 | $24,356 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 35 | $23,317 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 32 | $16,654 |
| SymbicortBudesonide/Formoterol Fumarate | 41 | $10,261 |
| DuleraMometasone/Formoterol | 25 | $8,406 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $92 | $1,235,20086 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Nucala, Incruse Ellipta | $348 | $302,020484 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $410 | $33,57876 claims |
| MerckDulera | $89 | $8,40625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Greenville
- Ogugua ObiGreenville$16K
- Michael PritchettPinehurst$1.3M
- Michael WertGreensboro$412K
- Eugene BleeckerWinston Salem$357K
- Bradley IcardPinehurst$299K
- James DonohueChapel Hill$271K
- Eric MeltzerDurham$262K
- Daniel BreaultWilmington$257K
- Scott SkiboPinehurst$229K
- Jill OharWinston Salem$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.